Game-Changer? Wegovy Cuts Heavy Drinking in Alcohol Addiction Trial
The 26-week trial found semaglutide cut heavy drinking days more than placebo and produced an average 11.2 kg weight loss.
7 Articles
7 Articles
Game-Changer? Wegovy Cuts Heavy Drinking in Alcohol Addiction Trial
(MedPage Today) -- People with obesity and alcohol use disorder had fewer heavy drinking days while on semaglutide (Wegovy), a Danish randomized trial showed. Alongside cognitive behavioral therapy, adults receiving a 2.4-mg weekly dose of the...
Weight-loss drug semaglutide reduces heavy alcohol drinking in new clinical trial
A recent study finds that the active ingredient in Wegovy and Ozempic significantly decreased heavy drinking in patients with obesity and alcohol use disorder. The findings suggest a potential new treatment path for millions of people.
A clinical trial shows that semaglutide reduces the days of excessive alcohol consumption in patients with obesity. A medical milestone. The entry Drugs for obesity reduces the days of excessive alcohol consumption, according to one study it was first published in La Voz de Michoacán.
A study with 108 adults has revealed that a weekly injection of semaglutide -a drug used to treat type 2 diabetes and obesity - reduced the number of days of excessive alcohol consumption. The entry Drugs for obesity reduces the days of excessive alcohol consumption, according to one study it was first published in Digital Process.
What did the Danish study find?
Weight loss drugs may help cut alcohol harm Coverage highlights a Danish study examining whether medications best known for weight loss and diabetes—such as Wegovy, Ozempic, and Mounjaro (GLP 1/GIP linked drugs)—could be repurposed to reduce harmful drinking in people with alcohol use disorder .…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
